FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...

Biocon said that the European Commission has granted marketing authorisation in the European Union (EU) for Biocon Biologics' Ustekinumab biosimilar 'YESINTEK'.

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the European Commission (EC) granted marketing authorisation in the ...

Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

Biologics Ltd (BBL), a subsidiary of Biocon Limited, has secured a major regulatory milestone with the European Commission ...

Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing ...